Sodium Thiosulfate to Preserve Cardiac Function in STEMI

Rationale: Timely and effective reperfusion by primary percutaneous coronary intervention (PPCI) is currently the most effective treatment of ST-segment elevation myocardial infarction (STEMI). However, permanent myocardial injury related to the ischemia and subsequent reperfusion is observed in the vast majority (88%) of patients and harbours a risk of heart failure development. Administration of hydrogen sulfide (H2S) has been shown to protect the heart from "ischemia reperfusion injury" in various experimental models. Data in humans suggests that the H2S-releasing agent sodium thiosulfate (STS) can be administered safely.

Objective: to evaluate the efficacy and safety of STS compared to placebo treatment on myocardial infarct size in patients presenting with STEMI and treated with PCI

Study design: a multicenter, double blind, randomized controlled clinical trial. A total of 380 patients, aged 18 years and above, undergoing primary PCI for a first STEMI and deemed amenable, by the investigator, to be treated with STS 12.5g intravenously (i.v.) or matched placebo immediately after arrival at the catheterization laboratory (cath-lab) and a repeated dose administered 6 hours after the first dose, on top of standard treatment. Primary endpoint is infarct size as measured with cardiac magnetic resonance imaging (CMR-imaging) 4 months after randomization.

Introduction and rationale:

Despite the recent advances in treatment, acute myocardial infarction (AMI) frequently results in permanent myocardial injury imposing an increased risk for adverse cardiac remodelling, diminished cardiac function and the development of heart failure. Decreased cardiac function after PPCI is associated with impaired prognosis. In addition to PPCI, cornerstones pharmacological treatment of myocardial infarction (MI) includes; (1) treatment direct against blood coagulation with platelet aggregation inhibitors, (2) cholesterol lowering treatment with statins; (3) sympathicus inhibition by beta-blocker treatment; and (4) inhibitors of the renin-angiotensin-aldosterone system. These therapies were successfully implemented over the last decades and resulted in substantial improvements of prognosis after AMI.

Although timely PPCI has a tremendous benefit in AMI, not only ischemia but also reperfusion itself is considered to cause myocardial injury and cardiomyocyte death. This phenomena is referred to as "ischemia reperfusion injury" in literature and is caused by the sudden restoration of blood flow and its accompanying intracellular acidity (pH) change and calcium overload, cardiomyocyte hypercontracture, myocardial inflammation, oxidative stress generation and mitochondrial permeability transition pore opening. Reducing ischemia reperfusion injury is expected to further decrease infarct size, decreasing adverse cardiac remodelling and improving cardiac function as well as clinical outcome.

The investigators expect a substantial beneficial effect of H2S in the prevention of ischemia reperfusion injury. H2S is the third endogenous gaseous transmitter next to carbon monoxide (CO) and nitric oxide (NO) and is involved as a physiological mediator in several body organ and tissue processes. H2S is synthesized endogenously by enzymatic and non-enzymatic pathways. A non-enzymatic pathway is by the reductive reaction with thiosulfate, with pyruvate acting as a hydrogen donor. Thiosulfate itself acts as an intermediate in the sulfur metabolism of cysteine and is known as a metabolite of H2S and in that way also able to produce H2S, especially under hypoxic conditions.

H2S has been shown to protect from myocardial ischemia reperfusion injury in various experimental animal models; e.g. it reduces infarct size and apoptosis and attenuates cardiac function. Inhibition of leukocyte endothelial cell interactions, neutralization of reactive oxygen species (ROS) and the reduction of apoptotic signalling are the suggested as additional mechanisms underlying the cardioprotective effect of H2S. H2S has been shown to attenuate myocardial ischemia reperfusion in cellular, rodents and porcine animal models. H2S can be safely administered intravenously as STS to humans. STS has been demonstrated to detoxify cyanide poisoning in 1895 in dogs, is used in humans since 1933 for the treatment of cyanide intoxication, is used since the eighties for treatment of vascular calcifications in end-stage renal disease, and is used to prevent toxicity of cisplatin treatment. More recently, studies have shown STS can delay the progression of coronary artery calcification in haemodialysis patients. The aim of the GIPS-IV trial is to evaluate the efficacy and safety of STS compared to placebo treatment on myocardial infarct size in patients presenting with STEMI undergoing PPCI in a double blind randomized controlled clinical trial.

Study design:

The GIPS-IV trial is a multicenter, randomized, placebo-controlled, double blind trial. A total of 380 patients presenting with a first STEMI will be included. All patients will be randomly assigned, in a 1:1 ratio, to receive STS (12.5 mg iv) or matching placebo. Study medication will be administered twice. The first dose of study medication will be administered immediately after checking inclusion and exclusion criteria and obtaining verbal informed consent at the cath-lab. The second dose of study medication will be administered 6 hours later, at the Coronary Care Unit (CCU). The study will take place at the University Medical Centre of Groningen (UMCG), University Medical Center Utrecht (UMCU) and Treant Scheper hospital in Emmen, all high-volume centers with experience in care and research of patients with STEMI. The primary endpoint will be based on infarct size as measured by late gadolinium enhancement cardiac magnetic resonance imaging (LGE CMR)-imaging 4 months after STEMI, a period in which the remodelling of the heart is expected to be completed. LGE CMR-imaging is a well-recognized, validated, and highly reproducible technique. Total follow-up duration of the GIPS-IV trial is 2 years.

Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years;
* The diagnosis STEMI defined by (1.) chest pain suggestive for myocardial ischemia for at least 30 minutes, the time from onset of the symptoms less than 12 hours before hospital admission, and (2.) an electrocardiogram (ECG) recording with ST- segment elevation of more than 0.1 millivolt (mV) in 2 or more contiguous leads or presence of new left bundle branch block;
* Symptoms and/or ST-segment deviation should be present (persisting) at time of arrival in the cath-lab;
* Primary PCI is being considered as treatment;
* Patient is willing to cooperate with follow-up during 2 years.

Exclusion Criteria:

* Prior MI (STEMI/non-STEMI/acute coronary syndrome (ACS), unless maximum troponin T \< 50ng/L.
* Prior CABG;
* Prior PCI, complicated by periprocedural infarction, unless maximum troponin T \< 50 ng/L;
* Known cardiomyopathy;
* Previous hospitalization for heart failure;
* Active malignancy (requiring chemotherapy, radiation or surgery at the time of randomization), except for adequately treated non-melanoma skin cancer or other noninvasive or in situ neoplasm (e.g., cervical cancer in situ);
* History of chemotherapy;
* History of radiotherapy in chest region;
* Relieve of symptoms and complete ST-segment resolution prior to arrival at the cath-lab;
* Known permanent atrial fibrillation;
* Presentation with cardiogenic shock (systolic blood pressure \<90 mmHg);
* Severe hypertension (systolic blood pressure \>220 mmHg);
* Sedated and/or intubated patients;
* The existence of a condition with a life expectancy of less than 1 year;
* Contraindication for 3 Tesla (T) CMR-imaging (e.g. body weight \>150kg; known claustrophobia; 3 T magnetic resonance imaging (MRI) incompatible ferromagnetic objects in the body, end-stage renal disease);
* Pregnancy or breastfeeding women; women of childbearing potential with clinical suspicion of possible pregnancy;
* A condition which, according to the clinical judgment of the investigator and/or treating physician, does not allow the patient to successfully participate in the study.
* Contraindication for metoclopramide (e.g. Parkison; epilepsy)